TON - ASH 2015 - Multiple Myeloma

Researchers reported results of a real-world prospective study that evaluated different geriatric assessment tools and comorbidity indices as well as standard disease-related prognostic factors in consecutive unselected patients aged >65 years with symptomatic multiple myeloma (MM).
Researchers reported results of a population-based study examined sex, race, and age-stratified differences in incidence, mortality, and survival from 1973 to 2012 for 89,867 myeloma patients by using national epidemiologic data.
Researchers presented results of patient-reported assessments of general health status as well as pain severity and interference using pooled data from 3 denosumab registrational trials that had enrolled patients with advanced cancers including multiple myeloma (MM).
Researchers reported results of an analysis using national epidemiologic data and self-reported data from the Medicare Health Outcomes Survey that determined the prevalence of falls in older adults with newly diagnosed multiple myeloma (MM) and examined associations between falls and functional status, comorbidities, and self-reported health.
Beth Faiman elaborates on her idea wish list of resources and tools that would help her to better manage patients on oral oncolytics.
Beth Faiman argues that patient support services are integral in her role as a nurse because they aid in getting patients the treatments they need, promote adherence, and provide patient education.
Researchers presented 2-year follow-up safety and efficacy results of a phase 2 open-label study that compared the efficacy and safety of combination therapy with the anti-SLAM7 monoclonal antibody elotuzumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (RRMM).
Researchers presented updated safety and efficacy results of a 2-part study (GEN503) that evaluated combination therapy with the anti-CD38 monoclonal antibody daratumumab plus lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (RRMM).
Researchers reported results of a global, multicenter, retrospective International Myeloma Working Group study that assessed the current treatment approaches utilized for initial treatment after first relapse and salvage treatment of patients with multiple myeloma (MM), and examined patient outcomes following successive therapies with the goal of examining the natural history of relapsed MM.
Researchers presented results of the randomized, placebo-controlled phase 3 Tourmaline-MM1 study that evaluated the benefit of adding the oral proteasome inhibitor ixazomib to the lenalidomide and dexamethasone (Rd) backbone compared with placebo plus Rd in patients with relapsed and/or refractory multiple myeloma (RRMM).
Page 1 of 3
Results 1 - 10 of 23